leisure time -WSS

leisure time

author：leisure time 2025-09-28 23:44:50 - browse：9

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Supreme Court wrestles with OxyContin maker's bankruptcy deal

leisure time

hotspot

WSS

Spinal cord stimulation reduces pain in amputees, study finds

Slovenia has suffered its worst

NFL doctors' conflicts of interest could endanger players, report says

Pennsylvania man bitten on the head by bear during attack in his garage

STAT letters to the editor on burnt

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

explore

leisure time

hotspot

Medicare details structure of new drug price negotiation program

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

United colonoscopy coverage change 'may cost lives,' doctors say

Americans' trust in science, scientist continues decline: Report

Dobbs anniversary: the lost opportunity of abortion as health care

Teach medical students about patients with intellectual disabilities

Duchenne breakthrough therapy leaves behind pioneering families

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

focus

Restaurant meals are packed with calories, and we still keep eating them

Pharma patents targeted by Biden in move to slash drug prices

Pharma patents targeted by Biden in move to slash drug prices

AI models in health care face new federal disclosure requirements

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

How CRISPR works, explained in two minutes

explore

leisure time

hotspot

hotspot